Comparison of pain during intravitreal dexamethasone, ranibizumab and aflibercept injection
| Autor: | Reşat Duman, Rahmi Duman, Elif Ertan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Dexamethasone Macular Edema Ranibizumab Ophthalmology medicine Eye Pain Humans Prospective Studies Glucocorticoids Pain Measurement Aflibercept business.industry Aflibercept Injection Middle Aged Receptors Vascular Endothelial Growth Factor Intravitreal Injections Female Implant business Follow-Up Studies Optometry medicine.drug |
| Zdroj: | Clinical and Experimental Optometry. 103:630-633 |
| ISSN: | 1444-0938 0816-4622 |
| DOI: | 10.1111/cxo.12974 |
| Popis: | This study aimed to compare pain scores of patients during intravitreal aflibercept, ranibizumab or dexamethasone implant injection procedures.This study included 162 eyes of 162 patients, who received intravitreal ranibizumab, aflibercept or dexamethasone implant injections at our clinic. Following the injection, patients were asked to rate their pain from 0 (no pain) to 10 (worst pain) using a visual analogue pain score survey (VAS). VAS was evaluated according to age, sex, indication for the injection, number of previous intravitreal injections, and lens status in the study eye.The mean VAS in the ranibizumab, aflibercept or dexamethasone implant groups was 3.38 ± 2.31, 3.82 ± 2.46, and 3.61 ± 2.94, respectively. Female patients reported a higher average pain score than male patients (p = 0.02). Also, phakic patients reported a higher average pain score than pseudophakic patients (p = 0.01). Pain did not significantly correlate with indication for the injection, number of injections, and injection drugs (p 0.05).Pain associated with intravitreal injection is generally mild and associated with sex, age, and lens status. There was no significant difference in pain between intravitreal injections of dexamethasone implant, ranibizumab or aflibercept. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text